Study Group: Physicians who Treat Stevens-Johnson Syndrome (US)
Council Members in this Study Group: 15
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
Sunil DhawanClinical Assistant Professor of Dermatology
STANFORD UNIVERSITY
Sunil Dhawan, MD, is a Clinical Assistant Professor of Dermatology at Stanford University. He has expertise in clinical dermatology including acne, rosacea, psoriasis, eczema, skin cancer, actinic keratosis, lasers and cosmetic dermatology, and managed...
Barry SchechterDirector of Corneal and External Diseases
FLORIDA EYE MICROSURGICAL INSTITUTE INCBarry Schechter, MD, is the Director of Department of Cornea and External Disease at Florida Eye Microsurgical Institute. Dr. Schechter's practice involves diseases of the ocular surface including dry eyes, allergies, infection; the latest in corneal,...
Ronald InnerfieldVice President of Clinical Affairs
Evidence Based Medicine, Inc.Ronald Innerfield, MD, FACE, is Chief of Clinical Trials and Epidemiology, Emeritus, at the Dorothy Bullock Memorial National Diabetes Center. He is also Vice President of Clinical Affairs of Evidence Based Medicine, a site management organization (SMO)...
- Darcy Ryan
Optometrist
Hertzog Eye AssociatesDarcy Ryan, OD, is an Optometrist at Hertzog Eye Associates, an Ophthalmological practice in Long Beach, California. He performs routine and specialty adult and pediatric eye exams. He treats and co-manages patients with almost every type of eye condition,...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
November 19, 2009
Leo Pharma completes merger pact with Peplin | www.pharmabiz.com
The recent merger of Peplin with Leo pharma is of some significance and will benefit both companies. It would have been difficult for Peplin to fully develop and market their flagship product alone.
-
Presta Trial shows good results for Enbrel
October 14, 2009
New data from PRESTA trial demonstrate the benefit of Enbrel in patients with psoriasis & psoriatic arthritis | www.pharmabiz.com
This trial showed predicatably good results for Enbrel in patients with psoriasis and psoriatic arthritis. This included improvement in signs and symptoms and quality of life. This will increase sales of Enbrel in the short term. However the two newer agents, Humira and Stelara have better efficacy, and more convenient dosing regimens. Both will be doing similar studies.
-
September 30, 2009
Controls to blood sugar 'cuts stroke risk' | www.barchester.com
There have been many epidemiologic studies showing a very tight correlation between baseline A1c and cardiovascular mortalityDespite this, five major randomized prospective studies have failed to show any macrovascular benefit for tighter glucose controlThe logical conclusion is that glucose is, therefore, a marker for increased mortality but not a modifiable risk factor thereofThis is why FDA has mandated cardiovascular safety for new antidiabetic agentsData dredging persists, however
-
Will the withdrawl of Efalizumab effect the biologic market?
April 15, 2009
Efalizumab withdrawn from US Market | www.medscape.com
This article is important in that the withdrawal of efalizumab by Genentech was appropriate in view of its serious side effect of progressive multifocal leukoencephalopathy (PML). This biologic agent was already declining in usage because of its other side effects, and the presence of other strong competitors with equal or higher efficacy and less side effects. This was to be compounded by the impending release of ustekinumab
-
Aurobindo terbinafine approval- what effect will this have?
January 21, 2009
Aurobindo Pharma gets approval for Terbinafine Tablets | myiris.com
This article is important in that it confirms another terbinafine competitor to the Novartis Lamisil brand is being released. The majority of terbinafine prescriptions in North America are generic. The market for this product will be good at least until more effective oral or topical agents are released. The majority of the prescriptions are for onychomycosis (toenail fungus). The newer products will be released in 3-4 years, at which time the market for terbinafine will shrink significantly.
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Contract Research Organization, Independent/Small
- Research Foundation
- Non-Academic Community Hospital or Clinic
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- Physician - Department Chair
- Physician - Division Head
- Project Manager
- Owner
- Vice President
- Allied Health Professional
Related Study Groups
GLG Live Meetings with this Study Group's Leading Experts (?)
May 22, 2008 | Boston
GLG Seminar: Diabetes and ObesityJune 20, 2007 | Chicago
GLGi: Diabetes and ObesityJune 19, 2007 | New York
GLGi: Diabetes and Obesity Grand RoundsGLG Webcasts & Teleconferences
Leading Experts in Physicians who Treat Stevens-Johnson Syndrome (US) have not participated in any GLG webcasts.